Asciminib (ABL001) | 99.88%(HPLC) | In Stock | Bcr-Abl inhibitor
Dual Drug Targeting of Mutant Bcr‐Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming Monotherapy Resistance - El Rashedy - 2018 - Chemistry & Biodiversity - Wiley Online Library
PDF] Allosteric Inhibition of ABL Kinases: Therapeutic Potential in Cancer | Semantic Scholar
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1 | Journal of Medicinal Chemistry
ABL-001 XLR Male Connector, 2 A, Stainless Steel
eMolecules ABL-001 | 1492952-76-7 | | 5mg, Quantity: Each of 1 | Fisher Scientific
Dual Drug Targeting of Mutant Bcr‐Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming Monotherapy Resistance - El Rashedy - 2018 - Chemistry & Biodiversity - Wiley Online Library
BCR-ABL inhibitor asciminib (ABL001) meets phase 3 primary endpoint in CML | BLU Ampersand, Inc.
ABL-001 – A Branded Store
ABL-001 | CAS# 1492952-76-7 | B1949 | BioVision, Inc.
Novartis receives FDA Breakthrough Therapy designations for STAMP inhibitor asciminib (ABL001)
Details of the molecular interactions between GNF-2 and ABL001 and the... | Download Scientific Diagram
ABL 001, Asciminib | New Drug Approvals
Molecules | Free Full-Text | Bcr-Abl Allosteric Inhibitors: Where We Are and Where We Are Going to
Efficacy of a combination of TKI and a novel allosteric inhibitor asciminib in chronic myeloid leukaemia | Faculty of Sciences, Engineering and Technology | University of Adelaide